Financial Survey: Alpha Teknova (TKNO) vs. Its Peers

Alpha Teknova (NASDAQ:TKNO – Get Rating) is one of 39 publicly-traded companies in the “Diagnostic substances” industry, but how does it contrast to its competitors? We will compare Alpha Teknova to related companies based on the strength of its profitability, dividends, institutional ownership, earnings, analyst recommendations, risk and valuation.

Profitability

This table compares Alpha Teknova and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alpha Teknova	-37.59%	-10.15%	-8.46%
Alpha Teknova Competitors	-2,192.62%	-1,216.29%	-29.93%

Institutional and Insider Ownership

25.5% of Alpha Teknova shares are held by institutional investors. Comparatively, 53.3% of shares of all “Diagnostic substances” companies are held by institutional investors. 10.2% of shares of all “Diagnostic substances” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and target prices for Alpha Teknova and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Teknova	0	0	4	0	3.00
Alpha Teknova Competitors	262	792	1254	40	2.46

Alpha Teknova currently has a consensus price target of $27.33, indicating a potential upside of 237.87%. As a group, “Diagnostic substances” companies have a potential upside of 90.20%. Given Alpha Teknova’s stronger consensus rating and higher probable upside, research analysts plainly believe Alpha Teknova is more favorable than its competitors.

Valuation & Earnings

This table compares Alpha Teknova and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Alpha Teknova	$36.89 million	-$9.80 million	-8.34
Alpha Teknova Competitors	$409.34 million	$33.17 million	-88.75

Alpha Teknova’s competitors have higher revenue and earnings than Alpha Teknova. Alpha Teknova is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Alpha Teknova beats its competitors on 7 of the 12 factors compared.

About Alpha Teknova (Get Rating)

Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.

Want More Great Investing Ideas?